Leukonecephalopathy Risk: Levamisole EMA Evaluation
- The European Medicines Agency (EMA) initiated a safety assessment of drugs containing levamisol on september 6, 2024, following reports of serious cases of leukoencephalopathy, a rare but severe...
- The assessment is being conducted by the EMA's Committee for Evaluation of Risks in Pharmacovigilance (PRAC).
- Leukoencephalopathy is a severe neurological condition affecting the white matter of the brain.
“`html
EMA Investigates Levamisol Drug Safety Following Reports of Severe neurological Side Effects
Table of Contents
Updated September 6, 2024, at 10:29 AM EDT
What Happened?
The European Medicines Agency (EMA) initiated a safety assessment of drugs containing levamisol on september 6, 2024, following reports of serious cases of leukoencephalopathy, a rare but severe neurological disorder, including one fatality. The investigation focuses on levamisol-based medications authorized in Hungary, Lithuania, Latvia, and Romania.
The assessment is being conducted by the EMA’s Committee for Evaluation of Risks in Pharmacovigilance (PRAC). The PRAC will investigate a potential link between levamisol use and the growth of leukoencephalopathy.
What is Leukoencephalopathy?
Leukoencephalopathy is a severe neurological condition affecting the white matter of the brain. This white matter consists of nerve fibers coated with myelin, crucial for efficient signal transmission. Damage to the myelin sheath disrupts interaction between different brain regions.
Symptoms of leukoencephalopathy can include confusion, muscle weakness, difficulty with coordination, speech problems, and vision impairment. Early diagnosis and treatment are critical, as the condition can be fatal or lead to permanent disability.
Wich Drugs are Affected?
Levamisol-based drugs are typically administered as a single oral dose and are used to treat infections caused by parasitic worms, especially in children. In the EU, these drugs are marketed under the names Decaris and Levamisol Arena, and are authorized for use in Hungary, Lithuania, Latvia, and Romania.
the EMA’s review will assess all available data, including reports of adverse drug reactions, to determine if regulatory action is needed to protect patients.
Timeline of Events
- September 6, 2024: The EMA announces the start of a safety assessment of levamisol-containing drugs.
- prior to september 6, 2024: Reports of serious cases of leukoencephalopathy, including one death, linked to levamisol use prompted the EMA review.
- Ongoing: The PRAC will conduct its investigation and issue recommendations.
What Does This Mean for Patients?
Patients currently taking levamisol-based medications should not stop taking thier medication without first consulting their doctor. Individuals experiencing any neurological symptoms, such as confusion, weakness, or difficulty with coordination, should seek immediate medical attention